Merus is focused on the use of two proprietary technologies to build a pipeline of innovative human therapeutic antibodies: the OligoclonicsTM and MeMoTM Technologies. With these technologies Merus generates combinations of therapeutic antibodies produced by a single cell with more potent biological activity than single antibodies. In the words of Cesar Milstein, Nobel Prize laureate for the discovery of monoclonal antibodies:

"All we seem to have acquired is the ability to select from an animal any of the antibodies from his repertoire. It is like selecting individual dishes from an elaborate menu. But surely our immunological gourmandising cannot be satisfied by simply choosing from a selection of what someone else has cooked. A gastronomer worth his salt wants to experiment with new ingredients, new combinations."